Livagen
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Livagen is a synthetic tetrapeptide made up of four amino acids — lysine, glutamic acid, aspartic acid, and alanine (Lys-Glu-Asp-Ala, or KEDA). It belongs to a group of short peptide bioregulators developed by Russian researchers led by Vladimir Khavinson, and is most often discussed in the context of the liver and cellular aging.
Livagen is described as a liver-oriented bioregulator, studied for its reported role in supporting hepatic function and influencing how genes are packaged and expressed within cells. Much of the interest around it comes from experiments examining chromatin — the structure that organizes DNA — in cells from older individuals.
The available evidence is limited and comes largely from preclinical and cell-based research. Livagen is not approved by any major regulator for therapeutic use and is sold for research purposes only.
How it works
In laboratory studies, Livagen has been reported to induce decondensation of tightly packed chromatin and to reactivate ribosomal genes that become silenced with age. Researchers have proposed that these short peptides may interact with DNA and regulatory regions to influence gene expression, a mechanism sometimes described as epigenetic in nature.
Within the liver, Livagen is studied for reported hepatoprotective and regulatory effects in aging and injury models. The precise molecular mechanism in humans has not been established, and these findings remain preliminary.
Reported benefits
- Support for hepatic function in preclinical liver-aging and injury models
- Reactivation of age-silenced ribosomal genes in cell studies
- Decondensation of chromatin in lymphocytes from older donors (studied for)
These are reported findings from preclinical research, not guaranteed outcomes in humans.
Considerations & side effects
Because human clinical trials are lacking, the safety profile of Livagen is not well characterized, and long-term effects in people are unknown. Any effects observed in cell and animal studies may not translate to humans.
Product purity and identity vary widely in the research-chemical market, which adds further uncertainty. Livagen is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is Livagen?
Livagen is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Ala (KEDA), part of the Khavinson family of short peptide bioregulators studied for effects on liver tissue and gene expression.
Is Livagen FDA-approved?
No. Livagen is not approved by the FDA or any major regulator for human therapeutic use, and is sold for research purposes only.
What is Livagen studied for?
It has mainly been studied in preclinical and cell-based research for its reported effects on chromatin structure, ribosomal gene activity, and hepatic function in aging models.
How strong is the evidence for Livagen?
Evidence is limited and largely preclinical, drawn from animal models and cell studies. There are no large human clinical trials establishing its effects or safety.
References
- Khavinson VKh, et al. Effects of Livagen peptide on chromatin activation in lymphocytes from old people. ↗
- Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. ↗
- Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors (experimental studies). ↗
Related compounds
AEDR tetrapeptide cardiovascular bioregulator. Supports cardiac gene regulation and cardiomyocyte metabolism. Studied for heart health and cardiovascular aging.
An oral Khavinson peptide bioregulator (peptide complex A-8) targeting the pineal gland — the oral-capsule analog to the injectable Epithalon lineage. The most-studied compound in the Khavinson framework, tied to melatonin, circadian rhythm, and anti-aging research.
EDL tripeptide bioregulator for liver and gastrointestinal health. Supports hepatic detoxification and GI tissue cellular regeneration.